Singhal Nimit, Kotasek Dusan, Parnis Francis X
Adelaide Cancer Centre, Ashford, South Australia, Australia.
Anticancer Drugs. 2009 Nov;20(10):953-5. doi: 10.1097/CAD.0b013e328330c7f0.
Chordomas are rare tumors arising from the axial skeleton. The disease is characterized by slow local growth, frequent local recurrences, and rare systemic spread. Surgery and local radiation remains the mainstay of treatment with minimal role of systemic therapy. Imatinib has been shown to be active in a phase II trial with symptomatic and radiological responses. We report a case where treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, induced symptomatic and radiological response in a patient with disease refractory to imatinib and vascular disrupting agent.
脊索瘤是一种起源于中轴骨骼的罕见肿瘤。该疾病的特点是局部生长缓慢、局部复发频繁且很少发生全身转移。手术和局部放疗仍然是主要的治疗方法，全身治疗作用极小。伊马替尼在一项II期试验中已显示出有活性，可产生症状性和影像学反应。我们报告了一例病例，一名对伊马替尼和血管破坏剂治疗无效的患者，使用表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼治疗后出现了症状性和影像学反应。
